Evaluating the Pieces of the Pharma Supply Chain - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluating the Pieces of the Pharma Supply Chain
After a year of increased attention on the pharmaceutical supply chain in Asia, what will be the region's short- and long-term role? This article contains bonus online-exclusive material.


Pharmaceutical Technology
Volume 33, Issue 1

Post-Heparin: Baxter Responds

Baxter International (Deerfield, IL) recalled thousands of vials of heparin in early 2008 after physicians in Baxter's pharmacovigilance group detected an increase in reported adverse reactions associated with the blood thinner in the United States (1, 2). Baxter and FDA later traced contamination (oversulfated chondroitin sulfate) to the product's active pharmaceutical ingredient (API), which was supplied by Scientific Protein Laboratories' (Waunakee, WI) Changzhou, China, facility (3, 4). FDA performed an inspection in February 2008, which resulted in an April 2008 warning letter to Changzhou SPL that noted significant deviations from current good manufacturing practices of APIs (5). Pharmaceutical Technology talked to Baxter International's director of corporate communications, Erin M. Gardiner, about the event.

PharmTech: What is Baxter's current take on the heparin incident?

Baxter: The heparin contamination was an unusual, extraordinary event that exposed vulnerabilities in a very small portion of Baxter's supply chain (as well as the other companies across the globe that experienced the same tampering) that we are aggressively addressing.

PharmTech: How much does Baxter source from China for its US products?

Baxter: Less than 1% of all Baxter products sold in the US include components sourced from China. The manufacturing facilities Baxter has in China produce products to be used in China and the Asia– Pacific market.

PharmTech: What changes has Baxter made to its supply chain?

Baxter: Broadly speaking, the heparin contamination crisis has reinforced the importance of staying focused long-term on supplier quality improvements and confirmed the prudence of the Baxter initiative, which we launched well before the heparin issue. The initiative includes enhancing our audit programs' frequency and duration, degree of scrutiny of new suppliers, and applying the best technology we can to enhance our supplier quality controls. These efforts, aimed at our operations globally, include:

  • A risk-based review of suppliers
  • Additional tamper-proof measures
  • Enhanced screening and testing technologies
  • Mapping our supply chain to reduce the 'number of links in the chain'
  • Increasing scrutiny of new suppliers
  • A revamping our audit program, including improved training, duration, and frequency.

PharmTech: What more can be done to ensure supply chains are safe?

Baxter: Resting on old standards, even ones that have worked for decades, is no longer enough.... Improvements have been made in the way we oversee our suppliers, the way we test, and how we anticipate the unimaginable. Baxter's name was on the product [heparin] and regardless of how, why or where this [contamination] happened, it's our responsibility to learn from the experience and take the appropriate actions to ensure this won't happen again.

References

1. Baxter Release, "Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/ML 10 and 30mL Multi-Dose Vials," Jan. 25, 2008.

2. Baxter Release, "Baxter to Proceed with Recall of Remaining Heparin Sodium Vial Products," Feb. 28, 2008.

3. FDA, "Questions and Answers on Heparin Sodium Injection," updated July 16, 2008, available at http://www.fda.gov/cder/drug/infopage/heparin/heparinQA.htm.

4. J. Woodcock, FDA CDER, "Statement before the House Subcommittee on Oversight and Investigations," Apr. 29, 2008.

5. HHS, "Warning Letter to Changzhou SPL Company, Ltd. from Richard L. Friedman, CDER," Apr. 21, 2008.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here